Raquel Nieto
Research Subjects
Raquel Nieto has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Carmina Gallardo
European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), Valdeolmos, 28130 Madrid, Spain
3 shared publications - Nadia Casado
European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), Valdeolmos, 28130 Madrid, Spain
2 shared publications - Alba Fresco-Taboada
Gold Standard Diagnostics Madrid (GSD Madrid), Calle de los Hermanos García Noblejas 39, 28037 Madrid, Spain
1 shared publication - Alejandro Monedero
Gold Standard Diagnostics Madrid (GSD Madrid), Calle de los Hermanos García Noblejas 39, 28037 Madrid, Spain
1 shared publication - Alejandro Soler
European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), Valdeolmos, 28130 Madrid, Spain
1 shared publication - Alicia Simón
European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), Valdeolmos, 28130 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
Epizootiology of African Swine Fever in the Croatian Wild Boar Population and the Estimation of the Surviving Dynamics (2023–2024)
This study integrates data on the prevalence, infection dynamics and risks associated with African swine fever virus (ASFV) outbreaks in Croatian wild boar during 2023–2024. Although the overall ASFV DNA prevalence in Croatia was 0.24%, the highest prevalence (2.29% in 2023 and 4.69% in 2024) was recorded in Vukovar-Srijem County. Genetic typing identified ASFV genotype II, subgroup 19, consistent with strains isolated from domestic pigs in Croatia and circulating in neighboring countries. Anti-ASFV specific antibodies were detected in 10.34% of wild boar tested in counties with previously reported DNA findings. In Vukovar-Srijem County, 4.60% of wild boar were positive for both, ASFV DNA and antibodies, suggesting ongoing virus infection, whereas the proportion of boar positive only for antibodies was 5.75%, indicating survival of acute infection. Statistical analysis revealed an increase in ASFV DNA detection from 2023 to 2024 (p = 0.043), with a higher prevalence in carcasses than in hunted animals (p = 0.001), highlighting the need for passive monitoring. While gender showed no statistical significance, a higher infection rate was observed in older animals (p = 0.001). The identified course of infection involved spillover events between domestic pigs and wild boar, with a significant anthropogenic influence.
Open AccessEpizootiology of African Swine Fever in the Croatian Wild Boar Population and the Estimation of the Surviving Dynamics (2023–2024)
This study integrates data on the prevalence, infection dynamics and risks associated with African swine fever virus (ASFV) outbreaks in Croatian wild boar during 2023–2024. Although the overall ASFV DNA prevalence in Croatia was 0.24%, the highest prevalence (2.29% in 2023 and 4.69% in 2024) was recorded in Vukovar-Srijem County. Genetic typing identified ASFV genotype II, subgroup 19, consistent with strains isolated from domestic pigs in Croatia and circulating in neighboring countries. Anti-ASFV specific antibodies were detected in 10.34% of wild boar tested in counties with previously reported DNA findings. In Vukovar-Srijem County, 4.60% of wild boar were positive for both, ASFV DNA and antibodies, suggesting ongoing virus infection, whereas the proportion of boar positive only for antibodies was 5.75%, indicating survival of acute infection. Statistical analysis revealed an increase in ASFV DNA detection from 2023 to 2024 (p = 0.043), with a higher prevalence in carcasses than in hunted animals (p = 0.001), highlighting the need for passive monitoring. While gender showed no statistical significance, a higher infection rate was observed in older animals (p = 0.001). The identified course of infection involved spillover events between domestic pigs and wild boar, with a significant anthropogenic influence.
- Open Access
Double Deletion of EP402R and EP153R in the Attenuated Lv17/WB/Rie1 African Swine Fever Virus (ASFV) Enhances Safety, Provides DIVA Compatibility, and Confers Complete Protection Against a Genotype II Virulent Strain
Background/Objectives: African swine fever virus (ASFV) is a devastating disease affecting domestic and wild suids and causing significant economic losses in the global pig industry. Attenuated modified live virus (MLV) vaccines are the most promising approaches for vaccine development. This study aimed to evaluate the safety and efficacy of four recombinant ASFV genotype II strains, derived from the non-hemadsorbing (non-HAD) attenuated isolate Lv17/WB/Rie1, through the single or simultaneous deletion of virulence-associated genes. Methods: Recombinant viruses were engineered by deleting the UK, EP402R, and EP153R genes, either individually or in combination. Four recombinant strains were evaluated for safety and efficacy in domestic pigs vaccinated intramuscularly with 102 TCID₅₀. Clinical signs, viremia, virus shedding, and antibody responses were monitored. Protection efficacy was assessed by challenging vaccinated pigs with the virulent genotype II Armenia07 strain. Additionally, a reversion-to-virulence study involving an overdose of the vaccine candidate was conducted to evaluate its stability through serial immunizations. Results: Deletion of the UK gene alone increased virulence, whereas the double deletion of EP402R and EP153R (Lv17/WB/Rie1-ΔCD) significantly enhanced safety while maintaining full protective efficacy. Vaccinated pigs exhibited reduced viremia, no virus shedding, and robust virus-specific antibody responses, achieving complete protection against Armenia07. The reversion-to-virulence study revealed potential but limited pathogenicity after multiple passages, indicating areas for improvement in vaccine stability. Conclusions: The Lv17/WB/Rie1-ΔCD strain demonstrates excellent safety and efficacy, along with potential DIVA (differentiating infected from vaccinated animals) compatibility, positioning it as a strong candidate for an ASFV MLV vaccine. Further research is needed to refine the vaccine and address the potential risks of reversion to virulence.
Open AccessDouble Deletion of EP402R and EP153R in the Attenuated Lv17/WB/Rie1 African Swine Fever Virus (ASFV) Enhances Safety, Provides DIVA Compatibility, and Confers Complete Protection Against a Genotype II Virulent Strain
Background/Objectives: African swine fever virus (ASFV) is a devastating disease affecting domestic and wild suids and causing significant economic losses in the global pig industry. Attenuated modified live virus (MLV) vaccines are the most promising approaches for vaccine development. This study aimed to evaluate the safety and efficacy of four recombinant ASFV genotype II strains, derived from the non-hemadsorbing (non-HAD) attenuated isolate Lv17/WB/Rie1, through the single or simultaneous deletion of virulence-associated genes. Methods: Recombinant viruses were engineered by deleting the UK, EP402R, and EP153R genes, either individually or in combination. Four recombinant strains were evaluated for safety and efficacy in domestic pigs vaccinated intramuscularly with 102 TCID₅₀. Clinical signs, viremia, virus shedding, and antibody responses were monitored. Protection efficacy was assessed by challenging vaccinated pigs with the virulent genotype II Armenia07 strain. Additionally, a reversion-to-virulence study involving an overdose of the vaccine candidate was conducted to evaluate its stability through serial immunizations. Results: Deletion of the UK gene alone increased virulence, whereas the double deletion of EP402R and EP153R (Lv17/WB/Rie1-ΔCD) significantly enhanced safety while maintaining full protective efficacy. Vaccinated pigs exhibited reduced viremia, no virus shedding, and robust virus-specific antibody responses, achieving complete protection against Armenia07. The reversion-to-virulence study revealed potential but limited pathogenicity after multiple passages, indicating areas for improvement in vaccine stability. Conclusions: The Lv17/WB/Rie1-ΔCD strain demonstrates excellent safety and efficacy, along with potential DIVA (differentiating infected from vaccinated animals) compatibility, positioning it as a strong candidate for an ASFV MLV vaccine. Further research is needed to refine the vaccine and address the potential risks of reversion to virulence.
- Open Access
Improving African Swine Fever Surveillance Using Fluorescent Rapid Tests
African swine fever (ASF) is a viral disease of swine with a huge impact due to its high mortality. Lately, the disease has actively spread around the world, affecting new areas from which it had been eradicated long ago. To date, ASF control is carried out by the implementation of strict biosecurity measures such as the early identification of infected animals. In this work, two fluorescent rapid tests were developed to improve the sensitivity of point-of-care diagnosis of ASF. For antigen (Ag) detection in blood, a double-antibody sandwich fluorescent lateral flow assay (LFA) was developed, employing a newly developed recombinant antibody to the VP72 of the virus. To complement the diagnosis, a double-recognition fluorescent LFA was developed using the VP72 for the detection of specific antibodies (Ab) in sera or blood. Both assays statistically improved the detection of the disease when compared to the commercial colorimetric assays INgezim® ASFV CROM Ag and INgezim® PPA CROM Anticuerpo, respectively, with higher statistical significance between 11 and 39 days post-infection. From the observation of results, it can be concluded that the combination of both Ag-LFA and Ab-LFA assays would facilitate the identification of infected animals, regardless of post-infection time.
Open AccessImproving African Swine Fever Surveillance Using Fluorescent Rapid Tests
African swine fever (ASF) is a viral disease of swine with a huge impact due to its high mortality. Lately, the disease has actively spread around the world, affecting new areas from which it had been eradicated long ago. To date, ASF control is carried out by the implementation of strict biosecurity measures such as the early identification of infected animals. In this work, two fluorescent rapid tests were developed to improve the sensitivity of point-of-care diagnosis of ASF. For antigen (Ag) detection in blood, a double-antibody sandwich fluorescent lateral flow assay (LFA) was developed, employing a newly developed recombinant antibody to the VP72 of the virus. To complement the diagnosis, a double-recognition fluorescent LFA was developed using the VP72 for the detection of specific antibodies (Ab) in sera or blood. Both assays statistically improved the detection of the disease when compared to the commercial colorimetric assays INgezim® ASFV CROM Ag and INgezim® PPA CROM Anticuerpo, respectively, with higher statistical significance between 11 and 39 days post-infection. From the observation of results, it can be concluded that the combination of both Ag-LFA and Ab-LFA assays would facilitate the identification of infected animals, regardless of post-infection time.